Solexa co-founder John Berriman has become chairman of Belgian biomarker company Pronota, the company said last week. Berriman is also chairman of Algeta and a director at MicroMet, Ablynx, and Oxxon Therapeutics.
Previously, he was a director at Abingworth Management, after working at Celltech Group. In addition, he was a director at Solexa, Epigenomics, Alnylam, and XCounter, and chairman of Chroma Therapeutics.
Berriman holds a chemical engineering degree from the University of Cambridge and an MBA from the London Business School.